Moderna gets $50 million to develop mRNA Ebola vaccine against Bundibugyo
Key points
- The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will “urgently accelerate development” of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo.
- Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate.
- The funding will simultaneously allow the company to ramp up manufacturing capabilities and ready large-scale Phase 2/3 trials in the event the vaccine makes it through early testing.
- The vaccine will use Moderna’s mRNA vaccine platform that allowed for rapid development of a COVID-19 vaccine during the pandemic.
- “[W]e believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats,” Moderna CEO Stéphane Bancel said in...
Quick Summary
The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will “urgently accelerate development” of three vaccine candidates against Bundibugyo ebolavirus
Why It Matters
This development is important because it may impact public opinion, policy decisions, and future developments related to Moderna gets $50 million to develop mRNA Ebola vaccine again.
Key Takeaways
- The global health organization Coalition for Epidemic Preparedness Innovations (CEPI) announced Monday that it will “urgently accelerate development” of three vaccine candidates against Bundibugyo ebolavirus (BDBV), pledging a little over $60 million in the effort to extinguish an outbreak currently raging out of control in the Democratic Republic of the Congo.
- Under the plans, CEPI has committed up to $50 million to US-based Moderna for preclinical development and Phase 1 clinical testing of its mRNA-based BDBV vaccine candidate.
- The funding will simultaneously allow the company to ramp up manufacturing capabilities and ready large-scale Phase 2/3 trials in the event the vaccine makes it through early testing.
- The vaccine will use Moderna’s mRNA vaccine platform that allowed for rapid development of a COVID-19 vaccine during the pandemic.
- “[W]e believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats,” Moderna CEO Stéphane Bancel said in a statement Monday.
📌 Source: Beth Mole
The BriefWire